TNFRSF1B and acute myeloid leukemia: During the treatment of acute myelocytic leukemia, the decrease in the number of TNFR2+ Tregs and the increase in the expression of IL-2 and IFN-γ can explain the combination of azacitidine and pabirestat can improve the therapeutic effect (69).